Other than TAT, Cetuximab (CTX, a monoclonal anti body (mAb) against epidermal growth factor receptor (EGFR)) was also used to target PEGylated liposomes loaded with Oxaliplatin at EGFR-expressing colorectal cancer [34]. Here, EGFR is linked to colorectal cancer.